Authorship note: js, nwm, and be contributed equally to this work. ks, mgf, and wch contributed equally to this work and are co-senior authors. conflict of interest: wch is a consultant for thermo fisher scientific, solasta ventures, mpm capital, ksq therapeutics, iteos therapeutics, tyra biosciences, jubilant therapeutics, function oncology, rappta therapeutics, frontier medicines, and calyx. ks receives grant funding from novartis and kronos bio, consults for and has stock options in auron therapeutics, and has served as an advisor for kronos bio and astrazeneca. mgf is a consultant for twentyeight-seven, inc., and blueprint medicines corporation. rb is a consultant for and owns equity in scorpion therapeutics and receives grant funding from merck and novartis. kll is a consultant for travera, bristol myers squibb, and integragen, oncodna; owns equity in travera; and receives grant funds from bristol myers squibb and eli lilly & co

HIGHLIGHTS

• who: Smitha Yerrum and colleagues from the DepartmentUSAMedical University have published the research: Authorship note: JS, NWM, and BE contributed equally to this work. KS, MGF, and WCH contributed equally to this work and are co-senior authors. Conflict of interest: WCH is a consultant for Thermo Fisher Scientific, Solasta Ventures, MPM Capital, KSQ Therapeutics, iTeos Therapeutics, Tyra Biosciences, Jubilant Therapeutics, Function Oncology, Rappta Therapeutics, Frontier Medicines, and Calyx. KS receives grant funding from Novartis and Kronos Bio, consults for and has stock options in Auron Therapeutics, and has served as an advisor for Kronos Bio and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.